Roivant Sciences (NASDAQ:ROIV) Shares Gap Up on Strong Earnings

Roivant Sciences Ltd. (NASDAQ:ROIV) gapped up before the market opened on Wednesday following a better than expected earnings announcement. The stock had previously closed at $28.21, but opened at $29.60. Roivant Sciences shares last traded at $31.7910, with a volume of 2,079,051 shares traded.

The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The firm had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter last year, the business posted ($0.29) EPS.

Trending Headlines about Roivant Sciences

Here are the key news stories impacting Roivant Sciences this week:

• Positive Sentiment: Roivant reported Q4 earnings that beat expectations, with EPS of -$0.28 versus the consensus estimate of about -$0.29, helping support investor confidence despite still being unprofitable. Roivant Sciences Ltd. (NASDAQ:ROIV) Q4 2025 Earnings Call Transcript
• Positive Sentiment: Management highlighted a swing to profitability in the quarter, which traders viewed as a major milestone for the stock and a sign the business is improving operationally. Roivant (ROIV) Climbs 15% on Swing to Profits
• Positive Sentiment: The company said it expects a $950 million Moderna-related payment in July and outlined several upcoming clinical readouts in the second half of 2026, which could be meaningful catalysts for the pipeline. Roivant anticipates $950M Moderna payment in July as it outlines 2H 2026 mosliciguat and IMVT-1402 readouts
• Neutral Sentiment: Investor attention is also centered on Roivant’s presentation and earnings-call details, which emphasized the company’s pipeline and strategic settlements rather than a major near-term revenue surprise. Roivant Sciences Ltd. 2025 Q4 – Results – Earnings Call Presentation
• Negative Sentiment: The quarter still showed weak fundamentals, including revenue below expectations and a reported loss in the latest filing, so some of the move appears driven by optimism around future catalysts rather than current profitability. Roivant Sciences Ltd. (ROIV) Reports Q4 Loss, Misses Revenue Estimates

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday. TD Cowen raised their price target on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday. Guggenheim raised their price target on Roivant Sciences from $28.00 to $30.00 and gave the stock a “buy” rating in a research note on Monday, February 9th. Jefferies Financial Group restated a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Finally, Citigroup lifted their target price on Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $33.05.

Insider Buying and Selling

In related news, CEO Eric Venker sold 200,000 shares of Roivant Sciences stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of $29.59, for a total value of $5,918,000.00. Following the sale, the chief executive officer directly owned 1,647,546 shares in the company, valued at $48,750,886.14. The trade was a 10.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jennifer Humes sold 13,538 shares of Roivant Sciences stock in a transaction that occurred on Wednesday, April 8th. The shares were sold at an average price of $28.37, for a total value of $384,073.06. Following the completion of the sale, the chief accounting officer owned 84,191 shares in the company, valued at approximately $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 1,332,563 shares of company stock worth $37,759,555. 10.80% of the stock is currently owned by insiders.

Institutional Trading of Roivant Sciences

Institutional investors have recently modified their holdings of the business. SBI Securities Co. Ltd. boosted its stake in shares of Roivant Sciences by 1,740.3% in the fourth quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock valued at $27,000 after buying an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Roivant Sciences by 226.0% in the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock valued at $25,000 after buying an additional 1,148 shares in the last quarter. Allworth Financial LP boosted its stake in shares of Roivant Sciences by 48.1% in the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after buying an additional 583 shares in the last quarter. Bessemer Group Inc. boosted its stake in shares of Roivant Sciences by 41.5% in the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after buying an additional 543 shares in the last quarter. Finally, Parallel Advisors LLC boosted its stake in shares of Roivant Sciences by 33.7% in the first quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock valued at $57,000 after buying an additional 520 shares in the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Roivant Sciences Price Performance

The stock has a market capitalization of $22.10 billion, a PE ratio of -51.47 and a beta of 1.14. The stock has a 50 day moving average of $28.46 and a two-hundred day moving average of $25.02.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.